IP Library Granted Patent US 8,999,675
Granted Patent B2
US 8,999,675 · App. 12/873,231 · Granted Apr 7, 2015

Dengue virus assay

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,999,675
App. No.
12/873,231
Granted
Apr 7, 2015
Kind
B2
Abstract

Nucleic acid assays for detecting nucleic acids of Dengue virus serotypes 1-4 derived from 5′ NTR.

Claims (19)

1. A method of determining whether a test sample contains Dengue virus, said method comprising the steps of:

(a) obtaining nucleic acids from the test sample;

(b) performing an in vitro nucleic acid amplification reaction using the nucleic acids obtained in step (a) as templates for amplification with a set of primers, whereby there is produced an amplification product if said test sample comprised nucleic acids of any of Dengue virus serotypes 1-4,

wherein the base sequence of a first member of said set of primers consists of a target-hybridizing sequence of SEQ ID NO:2, optionally joined to an upstream promoter sequence, and further optionally joined to an upstream tag sequence, wherein neither said upstream promoter sequence nor said upstream tag sequence can hybridize to the nucleic acid of any of Dengue virus serotypes 1-4 and participate in said in vitro nucleic acid amplification reaction in the absence of joining to said target-hybridizing sequence, and

wherein the base sequence of a second member of said set of primers consists of SEQ ID NO:14; and

(c) detecting, with a first detectably labeled hybridization probe, any of said amplification product that may have been produced in the in vitro nucleic acid amplification reaction, wherein the base sequence of said first detectably labeled hybridization probe is SEQ ID NO:22 or the complement thereof, allowing for substitution of RNA and DNA equivalent bases,

whereby detecting said amplification product determines that the test sample contains at least one of Dengue virus serotypes 1-4, and

whereby failing to detect said amplification product determines that the test sample does not contain Dengue virus.

2. The method of claim 1 , wherein obtaining step (a) comprises capturing nucleic acids from the test sample onto a solid support, and then isolating the solid support.

3. The method of claim 1 , wherein the in vitro nucleic acid amplification reaction in performing step (b) is an isothermal in vitro nucleic acid amplification reaction.

4. The method of claim 1 , wherein detecting step (c) comprises detecting by a procedure selected from the group consisting of luminometry and fluorometry.

5. The method of claim 1 , wherein detecting step (c) comprises detecting a chemiluminescent signal by luminometry.

6. The method of claim 1 , wherein the base sequence of said first member of said set of primers in performing step (b) consists of said target-hybridizing sequence of SEQ ID NO:2 joined to said upstream promoter sequence.

7. The method of claim 1 , wherein detecting step (c) comprises measuring an optical signal produced by said detectably labeled hybridization probe, and then comparing the measured optical signal to a cutoff value.

8. The method of claim 1 , wherein the test sample is selected from the group consisting of blood, blood products, and serum.

9. The method of claim 6 , wherein said set of primers further comprises a third member, and wherein the base sequence of said third member of said set of primers is SEQ ID NO:15.

10. The method of claim 1 , wherein said set of primers further comprises a third member, and wherein the base sequence of said third member of said set of primers is SEQ ID NO:15.

11. The method of claim 6 , further comprising a second detectably labeled hybridization probe, wherein the base sequence of said second detectably labeled hybridization probe is SEQ ID NO:23 or the complement thereof, allowing for substitution of RNA and DNA equivalent bases.

12. The method of claim 1 , further comprising a second detectably labeled hybridization probe, wherein the base sequence of said second detectably labeled hybridization probe is SEQ ID NO:23 or the complement thereof, allowing for substitution of RNA and DNA equivalent bases.

Assignments (6)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →